Hong Kong · Delayed Price · Currency is HKD Brii Biosciences Earnings Call Transcripts
Fiscal Year 2025
-
Strong progress in HBV clinical programs and expanded discovery capabilities drove revenue growth, while disciplined cost control and a robust cash position support long-term development. Key HBV study results and new pipeline programs are expected later in 2026.
-
Phase II-B HBV studies showed strong efficacy for BRII-179, with 61% antigen loss in responders. Cash reserves remain robust, supporting operations through 2028, while R&D and admin costs declined. Regulatory and market developments are expected to drive future growth.
Fiscal Year 2024
-
Year-end cash was CNY 2,413.4 million, with funds expected to support operations beyond 2028. Preliminary INSURE data support BRII-179-led patient enrichment as HBV trials advance and Phase III strategy is assessed.
-
Advanced HBV cure candidates received breakthrough therapy designation in China, with strong clinical progress and significant cost reductions. Cash reserves are sufficient through 2027, and key phase II data readouts are expected in Q4 2024.